We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

113 hedge funds and large institutions have $119M invested in Arbutus Biopharma in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more call options, than puts

Call options by funds: $4.81M | Put options by funds: $2.63M

11% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 37

0.26% more ownership

Funds ownership: 29.53% → 29.8% (+0.26%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 119 → 113 (-6)

9% less capital invested

Capital invested by funds: $131M → $119M (-$11.5M)

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

Holders
113
Holders Change
-6
Holders Change %
-5.04%
% of All Funds
1.9%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
41
Reduced
37
Closed
19
Calls
$4.81M
Puts
$2.63M
Net Calls
+$2.18M
Net Calls Change
+$3.47M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$5.48M
2
TSC
Two Seas Capital
New York
+$3.33M
3
BlackRock
BlackRock
New York
+$1.83M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.19M
5
FCM
FourWorld Capital Management
New York
+$648K

Top Sellers

1
N
Nuveen
North Carolina
-$3.27M
2
Goldman Sachs
Goldman Sachs
New York
-$2.07M
3
Prudential Financial
Prudential Financial
New Jersey
-$1.08M
4
BC
Brookfield Corp
Ontario, Canada
-$1.06M
5
CC
Centiva Capital
New York
-$894K
Name Holding Trade Value Shares
Change 		Change in
Stake
GWSG
101
GPS Wealth Strategies Group
Colorado
$2K -$2.98K -1,165 -62%
PA
102
Parallel Advisors
California
$2K +$433 +169 +31%
LC
103
Lindbrook Capital
California
$2K +$1.45K +565 New
Daiwa Securities Group
104
Daiwa Securities Group
Japan
$1K – – –
HFS
105
Hantz Financial Services
Michigan
$1K – – –
HIA
106
Harbor Investment Advisory
Maryland
$1K – – –
TWA
107
TCI Wealth Advisors
Arizona
$1K – – –
TF
108
TimeScale Financial
Massachusetts
$1K – – –
PHK
109
Point72 Hong Kong
Hong Kong
$1K +$1.08K +423 New
Bank of Montreal
110
Bank of Montreal
Ontario, Canada
$869 +$25.3K +9,882 +3%
CC
111
Centiva Capital
New York
– -$894K -300,000 Closed
PI
112
Putnam Investments
Massachusetts
– -$425K -142,677 Closed
Two Sigma Investments
113
Two Sigma Investments
New York
– -$355K -119,081 Closed
JF
114
Jump Financial
Illinois
– -$171K -57,300 Closed
Jacobs Levy Equity Management
115
Jacobs Levy Equity Management
New Jersey
– -$166K -55,713 Closed
HF
116
HRT Financial
New York
– -$150K -50,617 Closed
OIM
117
Oracle Investment Management
Connecticut
– -$149K -50,000 Closed
VCP
118
Verus Capital Partners
Arizona
– -$72K -28,600 Closed
D.E. Shaw & Co
119
D.E. Shaw & Co
New York
– -$59K -19,698 Closed
PP
120
Paloma Partners
Connecticut
– -$57K -18,978 Closed
AWA
121
Arete Wealth Advisors
Illinois
– -$45K -15,000 Closed
BCM
122
Bayesian Capital Management
New York
– -$36K -12,100 Closed
Russell Investments Group
123
Russell Investments Group
United Kingdom
– -$12K -4,120 Closed
UBS Group
124
UBS Group
Switzerland
– -$4K -1,298 Closed
GWS
125
Glassman Wealth Services
Virginia
– -$4K -1,238 Closed
2 3 4
5
6

ABUS Hedge Fund Activity: Q2 2022 in Review

113 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2022, worth a combined $119M — down 8.8% from $131M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of ABUS and 14 opened new positions — a net loss of 5 holders — while 37 trimmed existing stakes and 41 added.

The largest buyer was Millennium Management, adding an estimated $5.48M. The largest seller was Nuveen, cutting an estimated $3.27M.

  • 113 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2022, down from 119 in Q1 2022.
  • Funds reported $119M of Arbutus Biopharma stock for Q2 2022, down 8.8% quarter-over-quarter.
  • 14 funds opened new Arbutus Biopharma positions in Q2 2022 and 19 closed out, a net change of -5 holders.
  • The largest Arbutus Biopharma buyer in Q2 2022 was Millennium Management, an estimated $5.48M added.
  • The largest Arbutus Biopharma seller in Q2 2022 was Nuveen, an estimated $3.27M sold.

Based on aggregated 13F filings for Q2 2022.